|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar
|
|
4
|
Kim JJ and Tannock IF: Repopulation of
cancer cells during therapy: An important cause of treatment
failure. Nat Rev Cancer. 5:516–525. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zakaria N, Satar NA, Abu Halim NH, Ngalim
SH, Yusoff NM, Lin J and Yahaya BH: Targeting lung cancer stem
cells: Research and clinical impacts. Front Oncol. 7:802017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bertolini G, Roz L, Perego P, Tortoreto M,
Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S,
et al: Highly tumorigenic lung cancer CD133+ cells
display stem-like features and are spared by cisplatin treatment.
Proc Natl Acad Sci USA. 106:16281–16286. 2009. View Article : Google Scholar
|
|
7
|
Chaffer CL, Brueckmann I, Scheel C,
Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y,
Polyak K, et al: Normal and neoplastic nonstem cells can
spontaneously convert to a stem-like state. Proc Natl Acad Sci USA.
108:7950–7955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gupta PB, Fillmore CM, Jiang G, Shapira
SD, Tao K, Kuperwasser C and Lander ES: Stochastic state
transitions give rise to phenotypic equilibrium in populations of
cancer cells. Cell. 146:633–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iliopoulos D, Hirsch HA, Wang G and Struhl
K: Inducible formation of breast cancer stem cells and their
dynamic equilibrium with non-stem cancer cells via IL6 secretion.
Proc Natl Acad Sci USA. 108:1397–1402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gong Z, Chen D, Xie F, Liu J, Zhang H, Zou
H, Yu Y, Chen Y, Sun Z, Wang X, et al: Codelivery of salinomycin
and doxorubicin using nanoliposomes for targeting both liver cancer
cells and cancer stem cells. Nanomedicine (Lond). 11:2565–2579.
2016. View Article : Google Scholar
|
|
11
|
Xie F, Zhang S, Liu J, Gong Z, Yang K,
Zhang H, Lu Y, Zou H, Yu Y, Chen Y, et al: Codelivery of
salinomycin and chloroquine by liposomes enables synergistic
antitumor activity in vitro. Nanomedicine (Lond). 11:1831–1846.
2016. View Article : Google Scholar
|
|
12
|
Wang Y: Effects of salinomycin on cancer
stem cell in human lung adenocarcinoma A549 cells. Med Chem.
7:106–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Naujokat C and Steinhart R: Salinomycin as
a drug for targeting human cancer initiating cells. J Biomed
Biotechnol. 2012:9506582012. View Article : Google Scholar
|
|
14
|
Zhang Y, Zhang Q, Sun J, Liu H and Li Q:
The combination therapy of salinomycin and gefitinib using
poly(d,l-lactic-co-glycolic acid)-poly(ethylene glycol)
nanoparticles for targeting both lung cancer stem cells and cancer
cells. OncoTargets Ther. 10:5653–5666. 2017. View Article : Google Scholar
|
|
15
|
Ketola K, Hilvo M, Hyötyläinen T, Vuoristo
A, Ruskeepää AL, Orešič M, Kallioniemi O and Iljin K: Salinomycin
inhibits prostate cancer growth and migration via induction of
oxidative stress. Br J Cancer. 106:99–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao J, Xia Y, Chen H, Yu Y, Song J, Li W,
Qian W, Wang H, Dai J and Guo Y: Polymer-lipid hybrid nanoparticles
conjugated with anti-EGF receptor antibody for targeted drug
delivery to hepatocellular carcinoma. Nanomedicine (Lond).
9:279–293. 2014. View Article : Google Scholar
|
|
17
|
Kapoor DN, Bhatia A, Kaur R, Sharma R,
Kaur G and Dhawan S: PLGA: A unique polymer for drug delivery. Ther
Deliv. 6:41–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao J, Chen H, Song H, Su X, Niu F, Li W,
Li B, Dai J, Wang H and Guo Y: Antibody-targeted immunoliposomes
for cancer treatment. Mini Rev Med Chem. 13:2026–2035. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao J, Feng SS and Guo Y: Antibody
engineering promotes nanomedicine for cancer treatment.
Nanomedicine (Lond). 5:1141–1145. 2010. View Article : Google Scholar
|
|
20
|
Wang J, Wu Z, Pan G, Ni J, Xie F, Jiang B,
Wei L, Gao J and Zhou W: Enhanced doxorubicin delivery to
hepatocellular carcinoma cells via CD147 antibody-conjugated
immunoliposomes. Nanomedicine. Oct 16–2017.(Epub ahead of print).
pii: S1549-9634(17)30179-X.
|
|
21
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sos ML, Koker M, Weir BA, Heynck S,
Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P,
et al: PTEN loss contributes to erlotinib resistance in EGFR-mutant
lung cancer by activation of Akt and EGFR. Cancer Res.
69:3256–3261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
El-Sayed IH, Huang X and El-Sayed MA:
Surface plasmon resonance scattering and absorption of anti-EGFR
antibody conjugated gold nanoparticles in cancer diagnostics:
Applications in oral cancer. Nano Lett. 5:829–834. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang L, Mao H, Wang YA, Cao Z, Peng X,
Wang X, Duan H, Ni C, Yuan Q, Adams G, et al: Single chain
epidermal growth factor receptor antibody conjugated nanoparticles
for in vivo tumor targeting and imaging. Small. 5:235–243. 2009.
View Article : Google Scholar
|
|
25
|
Cushing BL, Kolesnichenko VL and O'Connor
CJ: Recent advances in the liquid-phase syntheses of inorganic
nanoparticles. Chem Rev. 104:3893–3946. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Allen TM: Ligand-targeted therapeutics in
anticancer therapy. Nat Rev Cancer. 2:750–763. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Auffan M, Rose J, Bottero JY, Lowry GV,
Jolivet JP and Wiesner MR: Towards a definition of inorganic
nanoparticles from an environmental, health and safety perspective.
Nat Nanotechnol. 4:634–641. 2009. View Article : Google Scholar : PubMed/NCBI
|
